>>Signaling Pathways>> Microbiology & Virology>> HCV>>PSI-352938 (PSI-938)

PSI-352938 (PSI-938) (Synonyms: PSI-938)

Catalog No.GC33971

PSI-352938(PSI-938)(PSI-938)은 C형 간염 바이러스(HCV) 뉴클레오티드 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

PSI-352938 (PSI-938) Chemical Structure

Cas No.: 1231747-17-3

Size 가격 재고 수량
1mg
US$717.00
재고 있음
5mg
US$1,434.00
재고 있음
10mg
US$2,436.00
재고 있음
20mg
US$4,302.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of PSI-352938 (PSI-938)

PSI-352938 (PSI-938) is a hepatitis C virus (HCV) nucleotide inhibitor.

PSI-352938 (PSI-938) and PSI-353661 inhibit HCV genotype (GT) 1b replicon replication with 50% effective concentrations (EC50s) of 0.13±0.076 μM and 3.0±1.4 nM, respectively, and are similarly active against GT 1a and 2a replicons and infectious viruses. Metabolism of PSI-352938 and PSI-353661 generates the same 5′-triphosphate metabolite, PSI-352666, which is similarly active against NS5B polymerases from GT 1 to 4[1]. PSI-352938 (PSI-938) is a novel cyclic phosphate prodrug of β-D-2′-deoxy-2′-α-fluoro-2′-β-C-methylguanosine 5′-monophosphate that has potent activity against HCV. PSI-352938 (PSI-938) has similar activity against genotype 1a, 1b, and 2a replicons, with EC50s ranging from 0.13 to 0.20 μM and EC90 values ranging from 0.35 to 0.74 μM. PSI-352938 (PSI-938) also effectively inhibits HCV replication in the infectious virus assays: the EC50 and EC90 values are 0.28±0.083 μM and 0.63±0.018 μM, respectively, against the H77 infectious virus and 0.39±0.31 μM and 1.16±0.64 μM, respectively, against the JFH-1 infectious virus. In contrast, PSI-352938 is not active against HBV or HIV up to the highest concentration tested (EC50>100 μM)[2].

[1]. Lam AM, et al. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol. 2011 Dec;85(23):12334-42. [2]. Lam AM, et al. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine. Antimicrob Agents Chemother. 2011 Jun;55(6):2566-75.

Protocol of PSI-352938 (PSI-938)

Cell experiment:

GT 1a, 1b, and 2a replicon cells are cultured in the presence of G418 (0.75 mg/mL for GT 1a, 0.25 mg/mL for GT 1b and 2a) and increasing concentrations of PSI-352938 (PSI-938) or PSI-353661 starting at their respective EC50 or EC90. As a no-compound control, replicon cells are maintained in parallel in the equivalent percent volume (0.2%) of DMSO. Cells are passaged whenever they reach ∼80% confluence and replenished with G418 medium containing fresh compound. At various passages, cells are tested for sensitivity to PSI-352938 (PSI-938) and PSI-353661. For each assay, 3-fold dilutions of test compound are added to cells in duplicate and incubated at 37°C in a humidified 5% CO2 atmosphere for 4 days. Inhibition of HCV replicon RNA replication is determined by real-time PCR (RT-PCR) using primers that anneal to the 5′ untranslated region or by measuring the levels of luminescence expressed via the firefly or Renilla luciferase reporter gene using the Bright-Glo or Renilla-Glo reagent, respectively. EC50 and EC90, the concentrations at which 50% and 90% inhibition are achieved, are determined using GraphPad Prism software. Aliquots of cells are also saved for RNA isolation, cDNA synthesis, and PCR amplification for sequencing analysis[1].

References:

[1]. Lam AM, et al. Hepatitis C virus nucleotide inhibitors PSI-352938 and PSI-353661 exhibit a novel mechanism of resistance requiring multiple mutations within replicon RNA. J Virol. 2011 Dec;85(23):12334-42.
[2]. Lam AM, et al. Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine. Antimicrob Agents Chemother. 2011 Jun;55(6):2566-75.

Chemical Properties of PSI-352938 (PSI-938)

Cas No. 1231747-17-3 SDF
Synonyms PSI-938
Canonical SMILES O=P1(OC(C)C)OC[C@]2([H])[C@@]([C@@](C)(F)[C@H](N3C(N=C(N)N=C4OCC)=C4N=C3)O2)([H])O1
Formula C16H23FN5O6P M.Wt 431.36
Solubility Soluble in DMSO Storage Store at -20°C
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of PSI-352938 (PSI-938)

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.3182 mL 11.5912 mL 23.1825 mL
5 mM 0.4636 mL 2.3182 mL 4.6365 mL
10 mM 0.2318 mL 1.1591 mL 2.3182 mL
  • Molarity Calculator

  • Dilution Calculator

  • Molecular Weight Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

In vivo Formulation Calculator (Clear solution) of PSI-352938 (PSI-938)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

리뷰

Review for PSI-352938 (PSI-938)

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PSI-352938 (PSI-938)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.